MA29620B1 - Nouveau derive de 1,4-benzothiazepine-1,1-dioxyde presentant des proprietes ameliorees, procede pour sa preparation, medicaments contenant ce compose, et son utilisation - Google Patents
Nouveau derive de 1,4-benzothiazepine-1,1-dioxyde presentant des proprietes ameliorees, procede pour sa preparation, medicaments contenant ce compose, et son utilisationInfo
- Publication number
- MA29620B1 MA29620B1 MA30557A MA30557A MA29620B1 MA 29620 B1 MA29620 B1 MA 29620B1 MA 30557 A MA30557 A MA 30557A MA 30557 A MA30557 A MA 30557A MA 29620 B1 MA29620 B1 MA 29620B1
- Authority
- MA
- Morocco
- Prior art keywords
- same
- benzothiazepine
- novel
- improved properties
- medicaments containing
- Prior art date
Links
- IVGHNDNOFMTFMK-UHFFFAOYSA-N 1$l^{6},4-benzothiazepine 1,1-dioxide Chemical class O=S1(=O)C=CN=CC2=CC=CC=C12 IVGHNDNOFMTFMK-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000003524 antilipemic agent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005033100A DE102005033100B3 (de) | 2005-07-15 | 2005-07-15 | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29620B1 true MA29620B1 (fr) | 2008-07-01 |
Family
ID=37575930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30557A MA29620B1 (fr) | 2005-07-15 | 2008-01-08 | Nouveau derive de 1,4-benzothiazepine-1,1-dioxyde presentant des proprietes ameliorees, procede pour sa preparation, medicaments contenant ce compose, et son utilisation |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20080207592A1 (enExample) |
| EP (1) | EP1907370B1 (enExample) |
| JP (1) | JP2009501178A (enExample) |
| KR (1) | KR20080027841A (enExample) |
| CN (1) | CN101218217A (enExample) |
| AR (2) | AR058433A1 (enExample) |
| AT (1) | ATE423774T1 (enExample) |
| AU (1) | AU2006272043A1 (enExample) |
| BR (1) | BRPI0613041A2 (enExample) |
| CA (1) | CA2614697A1 (enExample) |
| DE (2) | DE102005033100B3 (enExample) |
| IL (1) | IL188606A0 (enExample) |
| MA (1) | MA29620B1 (enExample) |
| MX (1) | MX2008000355A (enExample) |
| NO (1) | NO20080728L (enExample) |
| NZ (1) | NZ565293A (enExample) |
| RU (1) | RU2008105741A (enExample) |
| TW (1) | TW200745070A (enExample) |
| WO (1) | WO2007009656A2 (enExample) |
| ZA (1) | ZA200710360B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006299091A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7943782B2 (en) * | 2007-10-19 | 2011-05-17 | Abbott Laboratories | Crystalline chemotherapeutic |
| US7960564B2 (en) * | 2007-10-19 | 2011-06-14 | Abbott Laboratories | Crystalline chemotherapeutic |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| EP3400944B1 (en) | 2010-11-04 | 2020-07-15 | Albireo AB | Ibat inhibitors for the treatment of liver diseases |
| AU2011326872C1 (en) | 2010-11-08 | 2015-02-19 | Albireo Ab | A pharmaceutical combination comprising an IBAT inhibitor and a bile acid binder |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Ｅａファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CA3011619C (en) | 2016-02-09 | 2024-01-02 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| RU2750944C2 (ru) | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
| RU2019100575A (ru) * | 2016-06-27 | 2020-07-28 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Способы синтеза |
| JP7328207B2 (ja) | 2017-08-09 | 2023-08-16 | アルビレオ・アクチボラグ | コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用 |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| SG11202012170PA (en) | 2018-06-20 | 2021-01-28 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| EP3921027B1 (en) | 2019-02-06 | 2023-07-19 | Albireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| EP3921028B1 (en) | 2019-02-06 | 2022-11-09 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| WO2021110884A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AR120682A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar |
| PE20230234A1 (es) | 2019-12-04 | 2023-02-07 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar |
| JP7696898B2 (ja) | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| AR120674A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiazepina y su uso como ácido biliar |
| TWI871392B (zh) | 2019-12-04 | 2025-02-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CN114761018B (zh) | 2019-12-04 | 2025-12-02 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| TWI865673B (zh) | 2019-12-04 | 2024-12-11 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| JP7748451B2 (ja) | 2020-08-03 | 2025-10-02 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4243831A1 (en) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| CA3198216A1 (en) | 2020-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| CN119053330A (zh) | 2022-04-22 | 2024-11-29 | 阿尔比里奥公司 | 皮下给药asbt抑制剂 |
| WO2023237728A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
| CA3259103A1 (en) | 2022-07-05 | 2024-01-11 | Albireo Ab | Benzothia (di)azepine compounds and their use as bile acid modulators |
| EP4629997A1 (en) | 2022-12-09 | 2025-10-15 | Albireo AB | Asbt inhibitors in the treatment of renal diseases |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107494A (en) * | 1994-09-13 | 2000-08-22 | G.D. Searle And Company | Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19916108C1 (de) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| DE10312963A1 (de) * | 2003-03-24 | 2004-10-07 | Aventis Pharma Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
-
2005
- 2005-07-15 DE DE102005033100A patent/DE102005033100B3/de not_active Expired - Fee Related
-
2006
- 2006-07-13 NZ NZ565293A patent/NZ565293A/en unknown
- 2006-07-13 DE DE502006002956T patent/DE502006002956D1/de not_active Expired - Fee Related
- 2006-07-13 EP EP06776212A patent/EP1907370B1/de not_active Not-in-force
- 2006-07-13 CN CNA2006800250068A patent/CN101218217A/zh active Pending
- 2006-07-13 AT AT06776212T patent/ATE423774T1/de not_active IP Right Cessation
- 2006-07-13 WO PCT/EP2006/006849 patent/WO2007009656A2/de not_active Ceased
- 2006-07-13 KR KR1020087001184A patent/KR20080027841A/ko not_active Withdrawn
- 2006-07-13 BR BRPI0613041-0A patent/BRPI0613041A2/pt not_active Application Discontinuation
- 2006-07-13 TW TW095125566A patent/TW200745070A/zh unknown
- 2006-07-13 RU RU2008105741/04A patent/RU2008105741A/ru not_active Application Discontinuation
- 2006-07-13 MX MX2008000355A patent/MX2008000355A/es not_active Application Discontinuation
- 2006-07-13 JP JP2008520795A patent/JP2009501178A/ja not_active Abandoned
- 2006-07-13 AR ARP060103010A patent/AR058433A1/es unknown
- 2006-07-13 CA CA002614697A patent/CA2614697A1/en not_active Abandoned
- 2006-07-13 AR ARP060103009A patent/AR055076A1/es unknown
- 2006-07-13 AU AU2006272043A patent/AU2006272043A1/en not_active Abandoned
-
2007
- 2007-11-29 ZA ZA200710360A patent/ZA200710360B/xx unknown
-
2008
- 2008-01-06 IL IL188606A patent/IL188606A0/en unknown
- 2008-01-07 US US11/970,293 patent/US20080207592A1/en not_active Abandoned
- 2008-01-08 MA MA30557A patent/MA29620B1/fr unknown
- 2008-02-08 NO NO20080728A patent/NO20080728L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101218217A (zh) | 2008-07-09 |
| TW200745070A (en) | 2007-12-16 |
| US20080207592A1 (en) | 2008-08-28 |
| DE102005033100B3 (de) | 2007-01-25 |
| WO2007009656A3 (de) | 2007-04-19 |
| CA2614697A1 (en) | 2007-01-25 |
| WO2007009656A2 (de) | 2007-01-25 |
| NZ565293A (en) | 2010-01-29 |
| NO20080728L (no) | 2008-02-08 |
| ATE423774T1 (de) | 2009-03-15 |
| MX2008000355A (es) | 2008-03-07 |
| AR055076A1 (es) | 2007-08-01 |
| EP1907370B1 (de) | 2009-02-25 |
| ZA200710360B (en) | 2008-11-26 |
| KR20080027841A (ko) | 2008-03-28 |
| DE502006002956D1 (de) | 2009-04-09 |
| EP1907370A2 (de) | 2008-04-09 |
| BRPI0613041A2 (pt) | 2010-12-14 |
| AU2006272043A1 (en) | 2007-01-25 |
| JP2009501178A (ja) | 2009-01-15 |
| RU2008105741A (ru) | 2009-08-20 |
| IL188606A0 (en) | 2008-04-13 |
| AR058433A1 (es) | 2008-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29620B1 (fr) | Nouveau derive de 1,4-benzothiazepine-1,1-dioxyde presentant des proprietes ameliorees, procede pour sa preparation, medicaments contenant ce compose, et son utilisation | |
| MA29619B1 (fr) | Derive de 1,1 -dioxyde de 1,4-benzothiazepine, procede de preparation, medicaments comprenant ce compose, et utilisation de celui-ci comme hypolipidemiant | |
| MA30819B1 (fr) | Nouvelle diphenylazetidinone substituee par l'acide piperazin-1-sulfonique et presentant des proprietes pharmacologiques ameliorees | |
| HRP20040686B1 (hr) | Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza | |
| EP2380850A4 (en) | MODIFIED SODIUM MONTMORILLONITE, PREPARATION METHOD AND USE | |
| MA29480B1 (fr) | Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation | |
| MA33358B1 (fr) | Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase | |
| MXPA04003007A (es) | Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades. | |
| MA33636B1 (fr) | Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine | |
| MA30781B1 (fr) | Inhibiteur de kinase | |
| MA33364B1 (fr) | Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine | |
| MA30883B1 (fr) | Nouveaux derives de 1,1 - dioxyde de 1.4 - benzothiepine substitues par des radicaux benzyle, leur procede de preparation, les produits pharmaceutiques comprenant ces composes et leur utilisation | |
| MA29311B1 (fr) | Derives d'isoxazolines et son nouveau procede de production | |
| MA31832B1 (fr) | Dérivés de quinazolinedione, leur préparation et leurs applications thérapeutiques | |
| MA30351B1 (fr) | Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation | |
| MA29264B1 (fr) | Pyroles et imidazoles substitues, compositions les contenant, procede de fabrication et utilisation | |
| MA38330B1 (fr) | Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre) | |
| MA30959B1 (fr) | Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp | |
| MA31325B1 (fr) | Nouveaux procedes | |
| MA31116B1 (fr) | Procede de synthese de derives de l'acide 3-amino-tetrahydro-furan-3-carboxylique et utilisation de ceux-ci en tant que medicaments | |
| MX2022006990A (es) | Forma cristalina de un derivado del acido 7h-benzo[7]anuleno-2-car boxilico. | |
| MY139454A (en) | 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | |
| GEP20084361B (en) | Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists | |
| MA33145B1 (fr) | Fluidifiants pour suspensions aqueuses de particules minerales et pates de liant hydraulique | |
| PE20120921A1 (es) | Compuestos eteres aralquil bencilicos, proceso de preparacion de los mismos, compuestos intermediarios, composicion farmaceutica y medicamento que contiene dichos compuestos |